Hologic completes acquisition of DRC
Bone densitometer firm Hologic has completed its purchase of Direct Radiography Corp. from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at around $20 million, consisting of $7 million in cash
Bone densitometer firm Hologic has completed its purchase of Direct Radiography Corp. from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at around $20 million, consisting of $7 million in cash and about 1.9 million shares of Hologic common stock. The purchase amount decreased sharply from the initial agreement, which was valued at about $30 million. Hologic was able to get some price concessions in exchange for a speedy closing, said David Ellenbogen, Hologic chairman and CEO.
As a result of the acquisition, Hologic receives about 90 employees, a 168,000-square-foot research, development, manufacturing, and administrative site in Newark, DE, 26 U.S. patents, and a number of foreign patents.
Hologic plans to market DRCs DirectRay digital radiography technology via a number of channels, including OEM opportunities. Discussions with several potential OEM clients are under way, Ellenbogen said.
The company will also participate in the retrofit sector, equipping recently purchased traditional x-ray rooms with DirectRay detectors to pave the way for PACS, he said. In addition to the firms first retrofit site at Brooke Army Medical Center in Fort Sam Houston, TX, DRC has installed a retrofit at an undisclosed location. DRC is taking orders now for retrofits.
Finally, Bedford, MA-based Hologic will continue DRCs direct sales efforts with its traditional iiRAD systems. In future development plans, Hologic expects to bring DirectRay technology suitable for fluoroscopy and mammography applications to market. Commercialization of these products will not occur for at least a year, however, Ellenbogen said.
© 1999 Miller Freeman, Inc.All rights reserved.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
